This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are
randomly assigned to the aripiprazole arm and are eligible to participate in the study, they
will begin by taking 5mg once daily of aripiprazole for two weeks, then 10mg once daily for
the remaining three weeks. Efficacy and safety measures will be performed at each visit.
Participants will be randomized to receive either memantine or placebo on a 1:1 basis. This
blinding will be maintained by the IDS pharmacy at the University of Chicago.